JW Pharmaceutical announced on the 20th that it has launched the tablet-type colon cleanser "Jaycle." Jaycle is a prescription medication taken for bowel cleansing before endoscopy and X-ray examinations.
Jaycle requires a total of 20 tablets to be taken in two doses, making it the least among currently available tablet-type colon cleansers in Korea and easy to swallow due to its film coating.
Existing powder or liquid formulations of colon cleansers often lead to adverse reactions such as nausea and headaches, while also diminishing the accuracy of examinations. The tablet formulation has reduced these reactions.
In fact, in the phase 3 clinical trial results for Jaycle, the incidence of nausea was 7.62%, lower than that of the control group (21.7%). Among participants who reported headaches, 8.49% were in the control group, whereas only 0.95% were in the Jaycle group. No exceptional adverse cases related to electrolyte imbalances were reported. The bowel cleansing effect was comparable to that of the control group, and the polyp and adenoma detection rates were also similar.
JW Pharmaceutical plans to expand the distribution of Jaycle to hospitals and clinics. A company official noted, "Jaycle is a next-generation colon cleanser that enhances patient medication convenience," adding, "It is expected to establish itself as a new alternative in the prescription market focused on hospitals and clinics."